NCT00485407已完成3 期
Guiding Dose Increases In Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine Concentrations: a Randomized, Double-Blind Study
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 377
- 试验地点
- 2
- 主要终点
- Test whether patients treated with atomoxetine 1.2 mg/kg/day who have sub-optimal clinical responses and peak plasma atomoxetine levels no higher than 800 ng/mL will benefit from a dose increase to 2.4 mg/kg/day
研究概览
简要总结
The purpose of this trial is to test the value of dose increases in patients with residual ADHD symptoms after treatment with the usual target dose of atomoxetine
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 6 Years 至 16 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatients who are at least 6 years of age and not more than 16 years of age at Visit 1
- •Patients must meet DSM-IV diagnostic criteria for ADHD (any subtype)
- •Patients must have laboratory results showing no significant abnormalities (significant would include laboratory deviations requiring acute medical intervention or further medical evaluation)
- •Patients must be of normal intelligence as assessed by the investigator (that is, without a general impairment of intelligence and likely, in the investigator's judgment, to achieve a score of greater than or equal to 70 on an IQ test)
- •Patients must be able to swallow capsules
排除标准
- •Patients who weigh less than 25 kg or greater than 70 kg at study entry
- •Patients with current or past Bipolar I or II disorder, psychosis, autism, Asperger's syndrome, or pervasive developmental disorder
- •Patients with a history of any seizure disorder (other than febrile seizures) or patients who have taken (or are currently taking) anticonvulsants for seizure control
- •Patients with a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions
- •Patients with cardiovascular disease or other conditions that could be aggravated by an increased heart rate or increased blood pressure
结局指标
主要结局
Test whether patients treated with atomoxetine 1.2 mg/kg/day who have sub-optimal clinical responses and peak plasma atomoxetine levels no higher than 800 ng/mL will benefit from a dose increase to 2.4 mg/kg/day
次要结局
- Assess the relationship between plasma atomoxetine concentration levels and ADHD symptom response
- Compare the efficacy of atomoxetine up to 2.4 mg/kg/day with atomoxetine at 1.2 mg/kg/day in reducing residual ADHD symptoms
- Assess the safety and tolerability of atomoxetine at doses up to 2.4 mg/kg/day compared to 1.2 mg/kg/day in patients with peak plasma atomoxetine concentration levels no higher than 800 ng/mL as assessed by AEs elicited during open-ended questioning
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)Carcinoma, HepatocellularNCT00490685Istituto Clinico Humanitas142
进行中（未招募）
不适用
Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment ResponseAttention Deficit Hyperactivity DisorderNCT03153488Massachusetts General Hospital60
已完成
1 期
Short-course Hypofractionated Radiotherapy for Localized Prostate CancerProstate CancerNCT00126165Alberta Health services72
招募中
不适用
MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon CancerColorectal CancerNCT06204484Sun Yat-sen University349
终止
1 期
A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)Alpha-1 Antitrypsin DeficiencyNCT02363946Arrowhead Pharmaceuticals65